SEPTEMBER 14, 2021

Biophytis announces its management will participate and meet with investors at the following upcoming events and conferences: H. C. Wainwright 23rd Annual Global Investment ConferenceSeptember 13 to 15 – Virtual Amsterdam MidCap EventSeptember 20 to 21 – Virtual Investor Access EventSeptember 27 to 28 – Paris HealthTech Innovation DaysOctober 4 to 5 – Paris European MidCap EventOctober 19 to 22 Galien Medstartup 2021October 25 to 29 – New York Geneva MidCap EventDecember 1 to 2 Fullscreen Mode

Read the press release »

AUGUST 16, 2021

Biophytis receives favorable recommendation from Data Monitoring Committee (DMC) based on safety analysis of Sarconeos (BIO101) to continue patients recruitment in the COVA study in COVID-19

Read the press release »

AUGUST 13, 2021

Biophytis announces today that it has performed the obligations imposed on it by (i) the judgment of the Commercial Court of Paris (Tribunal de commerce de Paris) of March 16, 2021 and (ii) the judgment of July 16, 2021 of the Enforcement Judge of the Judicial Court of Paris (Juge de l’exécution du Tribunal Judiciaire de Paris) (see press releases of March 19, 2021 and July 19, 2021, available on the Company’s website) in the case opposing Biophytis to Negma Group Ltd (“Negma”) in relation to the ORNANEBSA agreement entered into on August 21, 2019. As part of this performance,

Read the press release »